论文部分内容阅读
目的:研究增殖诱导配体(APRIL)mRNA及蛋白的表达与B细胞非霍奇金淋巴瘤(B-NHL)患者临床分期、肿瘤负荷及疗效的关系。方法:采用实时荧光定量聚合酶链反应(RFQ-PCR)和酶联免疫吸附试验(ELISA)方法,检测各期B-NHL患者化疗前后外周血单个核细胞和血浆中APRIL mRNA及蛋白含量的变化。结果:化疗前,B-NHLⅢ期及Ⅳ期患者APRIL mRNA及蛋白表达明显高于Ⅰ/Ⅱ期(P<0.05),但Ⅲ期与Ⅳ期之间差异无统计学意义(P>0.05);化疗后,Ⅲ期与Ⅰ/Ⅱ期及Ⅳ期差异无统计学意义(P>0.05),但Ⅳ期明显高于Ⅰ/Ⅱ期(P<0.05)。化疗后B-NHL患者进展(PD)组APRIL mRNA及蛋白表达显著高于完全缓解(CR)及部分缓解(PR)组,与无变化(NC)组差异无统计学意义(P>0.05),且CR、PR及NC组间差异无统计学意义(P>0.05)。结论:APRIL与B-NHL的分期、肿瘤负荷量及疗效密切有关,且可能成为有效治疗B-NHL的新靶点。
OBJECTIVE: To study the relationship between APRIL mRNA and protein expression and clinical stage, tumor burden and efficacy in patients with B-cell non-Hodgkin’s lymphoma (B-NHL). Methods: The changes of APRIL mRNA and protein in peripheral blood mononuclear cells and plasma before and after chemotherapy in B-NHL patients were detected by real-time fluorescent quantitative polymerase chain reaction (RFQ-PCR) and enzyme-linked immunosorbent assay (ELISA) . Results: Before chemotherapy, the mRNA and protein expressions of APRIL in stages Ⅲ and Ⅳ were significantly higher than those in stage Ⅰ / Ⅱ (P <0.05), but there was no significant difference between stage Ⅲ and Ⅳ (P> 0.05). After chemotherapy, there was no significant difference between stage Ⅲ and stage Ⅰ / Ⅱ and stage Ⅳ (P> 0.05), but stage Ⅳ was significantly higher than stage Ⅰ / Ⅱ (P <0.05). APRIL mRNA and protein expression in patients with progressive B-NHL (PD) after chemotherapy were significantly higher than those in patients with complete remission (CR) and partial remission (PR). There was no significant difference between the two groups (P> 0.05) There was no significant difference between CR, PR and NC (P> 0.05). Conclusions: APRIL is closely related to the stage of B-NHL, tumor burden and efficacy, and may be a new target for effective treatment of B-NHL.